Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Immunocore Holdings plc (IMCR)

Immunocore Q1 net income rises to $13.0 million; KIMMTRAK sales up 14% to $106.7 million

Positive Impact 3 of 5 earnings Written later

Immunocore reported first-quarter 2026 results with KIMMTRAK net sales of $106.7 million, up from $93.9 million a year earlier, and net income of $13.0 million versus $5.0 million. Operating income was $7.3 million compared with a $3.6 million loss a year earlier, though R&D expense rose to $61.1 million and operating cash flow was negative $13.8 million.

Key points

  • KIMMTRAK Q1 2026 net sales of $106.7 million, up from $93.9 million; U.S. sales $67.4 million, Europe $34.4 million
  • Net income of $13.0 million, or $0.25 diluted EPS, versus $5.0 million, or $0.10, in Q1 2025
  • R&D expense rose to $61.1 million from $56.5 million, driven by Phase 3 trial costs; SG&A fell to $37.9 million from $40.2 million
  • Cash, cash equivalents and marketable securities were $844.9 million as of March 31, 2026

The filing

CompanyImmunocore Holdings plc (IMCR)
Form8-K, current report
Filed with the SECMay 6, 2026, 7:09 AM ET
Accession number0001140361-26-019205

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.